The Supreme Court on Thursday handed a unanimous victory to a generic drug manufacturer, ruling that a company cannot be held liable for inducing patent infringement when federal law required it to copy the very drug label at issue. The decision in Teva Pharmaceuticals USA v. GlaxoSmithKline resolves a long-running dispute over the cholesterol drug carvedilol and draws a firm line on how far patent holders can stretch infringement claims against generic competitors.
Justice Neil Gorsuch wrote the opinion for a united bench, finding that Teva could not have "induced" doctors to prescribe carvedilol for a patented use when the Food and Drug Administration forced Teva to carry the same label language that described that use. The ruling overturns a Federal Circuit decision that had exposed Teva to significant liability and sends a clear signal about the limits of pharmaceutical patent enforcement.
Carvedilol, originally sold by GlaxoSmithKline under the brand name Coreg, treats heart failure and other cardiovascular conditions. Glaxo held a patent covering the drug's use for congestive heart failure, but patents on other uses had expired. Teva sought FDA approval to sell a generic version of carvedilol for only the non-patented uses, a process known as a "skinny label" under the Hatch-Waxman Act.
The Hatch-Waxman framework, passed in 1984, was designed to speed generic drugs to market. It lets generic makers file abbreviated applications and, when a brand-name drug has multiple approved uses, seek approval for only those uses not covered by active patents. The generic label is supposed to "carve out" the patented indications.
Teva did exactly that. It submitted a label that excluded the congestive heart failure indication. But the FDA rejected the proposed carve-out and required Teva to include language on its label that, Glaxo later argued, effectively described the patented use. Teva had no choice under federal law: the FDA mandated the label text.
Glaxo sued Teva for induced infringement, arguing that by distributing carvedilol with a label referencing the heart failure use, Teva encouraged doctors to prescribe the drug in a way that infringed the patent. The Federal Circuit agreed with Glaxo, holding that the label language was enough to establish inducement regardless of why it appeared on the label.
That ruling alarmed generic drug manufacturers and consumer health advocates. If a company could face patent liability for language the FDA itself required, the entire skinny-label pathway would be undermined. Generic makers would face an impossible bind: violate FDA labeling rules, or accept patent infringement exposure.
The case attracted broad interest. The Biden and then Trump administrations both urged the Court to take the case and side with Teva, a rare point of bipartisan agreement on pharmaceutical patent policy. As Courthouse News reported, the justices heard oral arguments in March and appeared skeptical of Glaxo's position from the start.
Writing for all nine justices, Gorsuch grounded the decision in the text of the Patent Act and basic principles of intent. To prove induced infringement, a patent holder must show the accused party took "active steps" to encourage infringement and intended to do so. Merely complying with a federal mandate, Gorsuch wrote, does not satisfy either element.
Gorsuch emphasized that Teva tried to avoid referencing the patented use. The company submitted a skinny label. The FDA overrode that choice. Holding Teva liable under those facts, the opinion stated, would punish a company for obeying the law.
The opinion also addressed broader concerns about the Hatch-Waxman balance. Congress designed the statute to encourage generic competition while protecting valid patents. Allowing inducement claims based on FDA-mandated label language would tilt that balance sharply toward brand-name manufacturers, discouraging generics from entering the market at all. The Court's willingness to issue a unanimous ruling on a complex statutory question underscores how clearly the justices saw the legal error below.
The practical stakes extend well beyond Teva and Glaxo. Generic drugs account for roughly 90 percent of prescriptions filled in the United States, and the skinny-label pathway is a critical tool for getting those drugs to patients faster and cheaper. Had the Court ruled for Glaxo, brand-name manufacturers would have gained a powerful weapon to delay or block generic competition, even after key patents expired.
Industry groups representing generic manufacturers praised the decision. Consumer advocates noted that the Federal Circuit's approach had already chilled some generic launches, with companies unwilling to risk inducement suits over label language they could not control.
The ruling does not strip patent holders of all remedies. Glaxo and other brand-name companies can still enforce patents through direct infringement claims or challenge generic applications before the FDA. What they cannot do, after Thursday's decision, is use government-mandated label text as the basis for an inducement theory.
The 9-0 outcome stands out in a term marked by sharp divisions on other major cases. The justices have split bitterly on questions involving executive power, immigration, and constitutional rights. On patent law, they found common ground.
That unanimity may reflect the clarity of the legal question. When a federal agency forces a company to include specific language on a product, holding that company liable for following the directive creates an obvious logical problem. No justice found a way to square Glaxo's theory with the inducement standard.
The decision also arrives at a moment when the Court faces heightened public scrutiny and political pressure from multiple directions. A clean, unanimous opinion on a technical but consequential issue gives the institution a chance to demonstrate functional consensus.
Gorsuch's opinion kept the reasoning narrow and textual, avoiding sweeping pronouncements about patent policy or FDA authority. That restraint is characteristic of the justice's approach and left little room for concurrences or dissents. The opinion resolves the specific question presented and leaves broader Hatch-Waxman disputes for another day.
Thursday's reversal adds to a growing list of cases in which the Supreme Court has corrected the Federal Circuit on patent questions. The specialized appeals court, which handles nearly all patent appeals, has faced criticism from both conservative and progressive legal scholars for interpretations that some argue favor patent holders at the expense of competition.
The justices did not explicitly criticize the lower court's reasoning in harsh terms, but the unanimous reversal speaks for itself. The Federal Circuit's rule would have created a regime where generic manufacturers faced liability for conduct compelled by a separate branch of the federal government. That outcome, the Court made clear, finds no support in the statute Congress wrote.
As Congress and the executive branch continue debating drug pricing and the scope of judicial power over regulatory questions, the Teva decision removes one obstacle to generic market entry. Whether legislators take further action to clarify the Hatch-Waxman framework remains an open question.
The case now returns to the lower courts for proceedings consistent with the Supreme Court's opinion. Glaxo's inducement claim against Teva is effectively dead, but the broader litigation history around carvedilol spans years and multiple legal theories. Authorities have not publicly indicated whether Glaxo intends to pursue any remaining claims on other grounds.
For the generic drug industry, the immediate effect is relief. Companies that delayed skinny-label filings out of inducement concerns now have clear Supreme Court authority confirming that FDA-mandated label language cannot form the basis of an inducement claim. That clarity should accelerate generic launches for drugs where some, but not all, patent-protected uses have expired.
The decision also reinforces a principle that matters beyond pharmaceuticals: the government cannot force you to do something and then let a private party sue you for doing it. That logic resonates across regulatory contexts, from environmental compliance to telecommunications standards. The Court's recent willingness to check lower court overreach on statutory interpretation questions suggests the justices will continue policing that boundary.
When the law tells you to put something on a label, you should not need a patent lawyer's permission to obey.
